However, the complex network of feedback loops and crosstalk with other signaling pathways often leads to resistance to single-agent PI3K/AKT inhibitors, highlighting the need for combination therapies and identification of novel regulators of this pathway in GBM [22]. The gene discussed is AKT1; the disease is glioblastoma.